Skip to main content
MRNA
NASDAQ Life Sciences

Moderna的癌症疫苗显示出复发率降低，FDA逆转了流感疫苗审查

feedReported by Wiseek News
Sentiment info
Positive
Importance info
8
Price
$50.305
Mkt Cap
$19.867B
52W Low
$22.28
52W High
$55.2
Market data snapshot near publication time

summarizeSummary

Moderna与Merck合作开发的个性化癌症疫苗已经展示出复发率降低，这标志着一个重要的临床里程碑。同时，FDA在白宫介入后逆转了其最初拒绝审查公司新季节性流感疫苗申请的决定。这一消息为Moderna的产品线提供了特定的积极更新，建立在最近的10-K（2026-02-20）中提到的“关键产品线进展”的基础上，并补充了积极的欧洲监管新闻（2026-02-27）。这些发展是强有力的催化剂，支撑着公司对多元化产品线增长的期望，包括流感、诺如病毒和肿瘤产品，于2027年开始。交易者将密切关注即将到来的第三阶段结果和进一步的监管进展，涉及这些和其他产品线候选者。

在该公告发布时，MRNA的交易价格为$50.31，交易所为NASDAQ，所属行业为Life Sciences，市值约为$198.7亿。 52周交易区间为$22.28至$55.20。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article